Is it Time to Dump Design Therapeutics Inc (DSGN) Stock After it Has Gained 11.26% in a Week?

The market has been high on Design Therapeutics Inc (DSGN) stock recently. DSGN gets a Bullish score from InvestorsObserver Stock Sentiment Indicator.

Design Therapeutics Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on DSGN!

See Full DSGN Report

What is Stock Sentiment?

Sentiment uses short term technical analysis to gauge whether a stock is desired by investors. As a technical indicator, it focuses on recent trends as opposed to the long term health of the underlying company. Updates for the company such as a earnings release can move the stock away from current trends. Sentiment is how investors, or the market, feels about a stock. There are lots of ways to measure sentiment. At the core, sentiment is pretty easy to understand. If a stock is going up, investors must be bullish, while if it is going down, sentiment is bearish. InvestorsObserver’s Sentiment Indicator looks at price trends over the past week and also considers changes in volume. Increasing volume can mean a trend is getting stronger, while decreasing volume can mean a trend is nearing a conclusion. For stocks that have options, our system also considers the balance between calls, which are often bets that the price will go up, and puts, which are frequently bets that the price will fall.

What's Happening With DSGN Stock Today?

Design Therapeutics Inc (DSGN) stock is trading at $2.47 as of 11:04 AM on Friday, Dec 1, a gain of $0.06, or 2.71% from the previous closing price of $2.40. The stock has traded between $2.39 and $2.51 so far today. Volume today is below average. So far 210,655 shares have traded compared to average volume of 555,352 shares. To see InvestorsObserver's Sentiment Score for Design Therapeutics Inc click here.

More About Design Therapeutics Inc

Design Therapeutics Inc is a preclinical-stage biopharmaceutical company. It is a pioneering novel small-molecule therapeutic candidate, called gene-targeted chimera, that are designed to be disease-modifying and target the underlying cause of inherited nucleotide repeat expansion diseases. Click Here to get the full Stock Report for Design Therapeutics Inc stock.